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Introduction
Longevity increase is increasingly recognized by economists to be an important part of economic growth and development. 1 Economists have also come to recognize that, in the long run, the rate of economic "growth…is driven by technological change that arises from intentional [research and development (R&D)] investment decisions made by profit-maximizing agents" (Romer (1990) ) and by public organizations such as the National Institutes of Health. In principle, technological change could be either disembodied or embodied in new goods. Solow (1960) hypothesized that most technological change is embodied: to benefit from technological progress, one must use newer, or later vintage, goods and services. Bresnahan and Gordon (1996) argued that "new goods are at the heart of economic progress, " and Hercowitz (1998, p. 223) also reached the "conclusion…that 'embodiment' is the main transmission mechanism of technological progress to economic growth."
In this paper, we will analyze the impact of pharmaceutical innovation on longevity and medical expenditure in Sweden during the period 1997-2010. According to the National Science Foundation, the pharmaceutical and medical devices industries are the most research intensive industries in the economy. Moreover, new drugs often build on upstream government research (Sampat and Lichtenberg (2011) ).
The analysis will be performed using aggregate data, as opposed to patient-level data. Grunfeld and Griliches (1960, p. 1) showed that "aggregation of economic variables can, and in fact frequently does, reduce…specification errors. Hence, aggregation does not only produce an aggregation error, but may also produce an aggregation gain." In particular, patient-level data are surely more subject to selection effects (the sickest patients might get the newest-or oldest-treatments) than aggregate data.
We will use longitudinal, disease-level data to estimate difference-in-differences models of the effect of pharmaceutical innovation on longevity. In essence, we will investigate whether the diseases that experienced more pharmaceutical innovation had larger increases in longevity.
Our models will include year and disease fixed effects, so they will control for the overall increase in Swedish longevity and for stable between-disease differences in mortality.
Pharmaceutical innovation can be measured in several different ways, because active substances are divided into different groups according to the organ or system on which they act 1 See e.g. Nordhaus (2002) and Murphy and Topel (2005) . Pharmaceutical innovation is likely to have affected medical expenditure as well as longevity. New drugs are generally more expensive than old drugs, so pharmaceutical innovation is likely to have increased pharmaceutical expenditure. We will investigate whether there were larger increases in expenditure on classes of drugs that experienced more pharmaceutical innovation. Previous research has shown that pharmaceutical innovation may also have on impact on other types of medical expenditure, especially expenditure on hospitals and nursing homes. We will investigate whether the diseases that experienced more pharmaceutical innovation had larger declines in hospital utilization. By combining our estimates of the effect of pharmaceutical innovation on longevity, pharmaceutical expenditure, and hospital utilization, we can obtain an estimate of the incremental cost-effectiveness (cost per life-year gained) of pharmaceutical innovation in Sweden during the period 2000-2009. We will pool data from several rich data sources. Longitudinal disease-level measures of pharmaceutical innovation will be constructed from Läkemedelsverket (Sweden's Medical Products Agency) 3 and from Thériaque. 4 Longitudinal disease-level data on mortality will be obtained from the WHO Mortality Database.
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Longitudinal disease-level data on hospital 2 The complete classification of metformin illustrates the structure of the code:
A Alimentary tract and metabolism (1st level, anatomical main group) A10 Drugs used in diabetes (2nd level, therapeutic subgroup) A10B
Blood glucose lowering drugs, excl. insulins (3rd level, pharmacological subgroup) A10BA
Biguanides (4th level, chemical subgroup) A10BA02 Metformin (5th level, chemical substance) http://www.whocc.no/atc/structure_and_principles/ 3 http://www.lakemedelsverket.se/Sok-efter-lakemedel-och-mediciner-i-Lakemedelsfakta/ 4 Thériaque (http://www.theriaque.org/) is a database of official, regulatory and bibliographic information on all drugs available in France, intended for health professionals. Funding is provided by the Centre National Hospitalier d'Information sur le Médicament. 5 http://www.who.int/healthinfo/morttables/en/ utilization will be obtained from Eurostat. 6 Longitudinal data on pharmaceutical expenditure and innovation, by drug class, will be obtained from the IMS Health MIDAS database. 7 Some additional data will be obtained from the OECD Health database.
In the next section we develop a model of the impact of pharmaceutical innovation on longevity. Descriptive statistics and estimates of age-at-death models are presented in section 3.
The effects of pharmaceutical innovation on hospital utilization and prescription drug expenditure are examined in sections 4 and 5, respectively. The cost-effectiveness of pharmaceutical innovation in Sweden is assessed in section 6. The final section contains a summary and conclusions.
Model of the impact of pharmaceutical innovation on longevity
To investigate the impact of pharmaceutical innovation on longevity in Sweden, we will estimate models of the following form: …, I; t = 1997,…,2010) where LONGEVITY it = a measure of longevity associated with disease i in year t Rx_MEASURE it = a measure related to pharmaceutical innovation associated with disease i in year t  i = a fixed effect for disease i  t = a fixed effect for year t 6 http://epp.eurostat.ec.europa.eu/portal/page/portal/statistics/search_database 7 IMS describes MIDAS as "a unique data platform for assessing worldwide healthcare markets. It integrates IMS national audits into a globally consistent view of the pharmaceutical market, tracking virtually every product in hundreds of therapeutic classes and providing estimated product volumes, trends and market share through retail and non-retail channels. MIDAS data is updated monthly and retains 12 years of history. The research design is similar to that used in two studies Lichtenberg (2005 Lichtenberg ( , 2009 ) has done with U.S. data.
 it = a disturbance A positive and significant estimate of  in eq.
(1) would signify that diseases for which there was more pharmaceutical innovation had larger increases in longevity. Now we will discuss how we will define and measure LONGEVITY it and Rx_MEASURE it , and why we do so.
Measurement of longevity.
Life expectancy at birth is probably the most commonly cited measure of longevity. However, this is not the measure of life expectancy we will use. The main reason is that life expectancy at birth (or at higher ages) cannot be measured for specific diseases. A more minor "disadvantage" of this indicator is that it is "hypothetical," rather than "actual": it is based on the period life The measures of longevity we will use will be based on the age distribution of deaths caused by a disease in a given year. These measures can easily be calculated from data contained in the WHO Mortality Database, which provides data on the number of deaths, by cause, age group, country, and year. The most informative measure is mean age at death.
10
A second measure is the fraction of deaths that occur above a given age, e.g. age 75.
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There is a potential pitfall in analyzing the relationship between pharmaceutical innovation related to a disease and the age distribution of deaths from the disease. Suppose that the introduction of a new drug for a disease reduces the number of people who die from the disease; people who would have died from the disease, absent the new drug, die from other diseases instead. Our estimates will not capture between-disease spillover effects. In principle, such between-disease spillover effects could be substantial. However, they appear to be quite modest in practice. Figure 1 shows that if the number of deaths, by cause, in 1997 had prevailed during the entire 1997-2010 period, mean age at death would have increased by almost exactly the same amount as it actually increased. Virtually all of the increase in mean age at death was 9 See http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_21.pdf, p. Lichtenberg (2012) showed that, in the case of France, when the number of drugs that can be used to treat a disease increases, the weighted mean vintage of drugs used to treat the disease increases several years later (due to gradual diffusion of new drugs).
The specific versions of eq. (1) we will estimate are: where AGE_DEATH it = mean age at death from disease i in year t AGE_GT75 it = the fraction of deaths from disease i in year t that occurred after age 75
In his model of endogenous technological change, Romer (1990) hypothesized an aggregate production function such that an economy's output depends on the "stock of ideas" that have previously been developed, as well as on the economy's endowments of labor and capital. Eqs. (2) and (3) may be considered health production functions, in which age at death is an indicator of health output or outcomes, and the cumulative number of drugs approved is analogous to the stock of ideas.
Age at death from a disease may depend on the number of chemical (or pharmacological) subgroups that have previously been developed to treat the disease rather than, or in addition to, the number of chemical substances (drugs) that have previously been developed to treat the disease. We will investigate this by estimating models like the following: Lichtenberg (2012) showed that, in the U.S., the rate of pharmaceutical innovation is not positively correlated with the rate of medical procedure innovation and may be negatively correlated with the rate of diagnostic imaging innovation.
This suggests that failure to control for other medical innovation is very unlikely to result in overestimation of the effect of pharmaceutical innovation on longevity growth, and may even result in underestimation of this effect.
In section 3 we will report estimates of eq. (2):
However, the number of people exposed to pharmaceutical innovation tends to be much larger than the number of people exposed to other types of medical innovation. http://www.who.int/classifications/icd/en/). Sweden began using the ICD-10 system to classify its mortality data in 1997.
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The most recent year for which mortality data are available for Sweden in the WHO Mortality Database is 2010. Our longevity analysis will therefore cover the period 1997-2010. The ICD-10 contains 12,131 distinct disease codes. These are grouped into 263 "blocks," such as "A00-A09 Intestinal infectious diseases," and "C30-C39 Malignant neoplasms of respiratory and intrathoracic organs."
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We will perform the analysis using data at the ICD-10 block level.
Descriptive statistics and estimates of age-at-death models
Descriptive statistics. Summary statistics on longevity and pharmaceutical innovation in Sweden are shown in Table 1 To illustrate the nature of the disease-specific data on pharmaceutical innovation, Table 2 lists Appendix Table 1 shows data on mortality and the number of chemical substances that had been commercialized in 1997 and 2010 for each of the 123 diseases (ICD-10 Blocks) in our sample.
Estimates of age-at-death models. Now we will present estimates of age-at-death models (eqs.
(2)-(4) and similar models). All models will be estimated by weighted least squares, weighting
by N_DEATHS it , the number of deaths from disease i in year t. This is appropriate because, due to the inclusion of fixed disease effects, we are in essence analyzing within-disease changes in age at death, and as shown in Figure 3 , the variance of these changes is much larger for diseases causing few deaths than it is for diseases causing many deaths. Also, disturbances will be clustered within diseases.
Estimates of key parameters from 36 different age-at death models are shown in Table 3 .
Estimates that are significantly different from zero (p-value < 0.05) are shown in bold. In models 1-18, the dependent variable is AGE_DEATH it . In model 1, the regressor is N_CHEM_SUBSTANCES i,t , the number of chemical substances indicated for disease i that had been commercialized by the end of year t. The coefficient is not statistically significant. In models 2 and 3, the regressors are N_CHEM_SUBSTANCES i,t-k , where k = 1 and 2, respectively. The coefficients in these models are also insignificant, indicating that mean age at death is not related to the number of substances that had been commercialized up to 2 years before. However, the coefficient on N_CHEM_SUBSTANCES i,t-3 in model 4 is positive and significant (p-value = 0.0354), indicating that mean age at death is related to the number of substances that had been commercialized up to 3 years before. The variable that is most strongly related to AGE_DEATH it (its coefficient has the highest Z value) is N_CHEM_SUBSTANCES i,t-6 (model 7). Since a new substance generally won't be widely used until a few years after it is commercialized, it is not surprising that the coefficients in models 4-11 are significant, but that the coefficients in models 1-3 aren't significant. Models 12-18 are similar to models 1-7, but the regressors are the number of chemical subgroups, rather than the number of chemical substances, that had been commercialized by the end of year t, t-1,…,t-6, respectively. None of the parameters in models 12-18 are significant.
Mean age at death is positively related to the number of substances that had been commercialized up to 3 years before, but not to the number of chemical subgroups commercialized.
In the remaining models (models 19-36) in Table 3 , the dependent variable is the fraction of deaths that occurred at an age greater than 75. This variable is measured much more precisely than mean age at death, but it is more difficult to interpret. Models 19-29 are analogous to models 1-11. The regressors are the number of chemical substances that had been commercialized by the end of year t, t-1,…,t-10, respectively. The parameters in all 11 equations are positive and highly significant (p-value < .0263). The coefficient in model 24 has the highest Z value; the number of chemical substances that had been commercialized by the end of year t-5
has the most significant effect on the fraction of deaths that occurred at an age greater than 75.
Models 30-36 are analogous to models 12-18; they examine the effect of the number of chemical subgroups that had been commercialized by the end of year t, t-1,…,t-6, respectively, on the fraction of deaths that occurred at an age greater than 75. None of the parameters in models 12-18 are significant: the change in the fraction of deaths at an age greater than 75 is unrelated to the growth in the number of subgroups.
Overall, the estimates in Table 3 provide support for the hypothesis that an increase in the number of substances that have been commercialized and that may be used to treat a disease causes a rightward shift of the age distribution of deaths from the disease several years later. Now we will estimate the magnitude of the increase in mean age at death that was attributable to growth in the number of substances commercialized. We do this by comparing the estimates of the year fixed effects ( t 's) in the following two versions of eq. (5):
Since eq. (6) does not control for the (contemporaneous or lagged) number of chemical substances ( is constrained to equal zero), the year fixed effects in this equation measure the unconditional mean age at death in each year (almost identical to the values reported in Table 1 ).
Eq. (7) controls for ("holds constant") the number of chemical substances commercialized up to six years earlier, so the year fixed effects in this equation measure the (counterfactual) mean age at death in each year, conditional on no pharmaceutical innovation.
The results of this calculation are shown in Figure 4 . As noted above, from 1997 to 2010, mean age at death increased by 1.88 years, from 78.40 to 80.28 years. The estimates of the year fixed effects of eq. (7) indicate that, holding constant the number of chemical substances commercialized up to six years earlier, mean age at death would have increased by 1.29 years, from 78.40 to 79.69 years. We therefore estimate that pharmaceutical innovation increased mean age at death in Sweden by 0.60 years (7.15 months) during the period 1997-2010, and that it accounted for almost 1/3 (31.6%) of the overall increase in mean age at death. It accounted for twice as large a fraction (63%) of the increase in the fraction of deaths that occurred at an age greater than 75.
The effect of pharmaceutical innovation on hospital utilization
Now we will examine the effect of pharmaceutical innovation on hospital utilization.
Annual data on the number of inpatient hospital days, hospital discharges, and average length of stay (ALOS), by diagnosis during the period 2000-2009, were obtained from Eurostat.
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Data on the number of hospital days and discharges and average length of stay, for all causes of diseases (ICD-10 codes A00-Z99) excluding external causes of morbidity and mortality (V00-Y98) and liveborn infants (Z38), are shown in Table 4 .
Eurostat hospital data, like WHO mortality data, are classified by ICD-10, but the hospital classification is somewhat different from the ICD-10 block classification shown in Appendix Table 1 . Appendix Table 2 shows data on the number of hospital discharges, days, and average length of stay, in 2009, by diagnosis as defined in the Eurostat classification.
We estimated relationships between hospital utilization and pharmaceutical innovation, such as the following:
where DAYS it = the number of hospital days for disease i in year t (t = 2000,…,2009) These equations were estimated by weighted least squares, weighting by the total number of hospital days for disease i during the entire period (DAYS i. = (1/10)  t DAYS it ). We also estimated similar equations in which the dependent variable was ln(DISCHARGES it ), where DISCHARGES it = the number of discharges for disease i in year t; in these equations, the weight used was the total number of discharges for disease i during the entire period (DISCHARGES i. ).
Estimates of the hospital utilization equations are shown in Table 5 . Disturbances are clustered within diseases in all models. In models 37-53, the dependent variable is ln(DAYS it ).
In models 37-47, the regressor is ln(N_CHEM_SUBSTANCES i,t-k ) for k = 0, 1,…, 10, respectively. The coefficients in the first four models are insignificant, but the coefficients in models 41-47 are negative and significant. This indicates that an increase in the number of drugs commercialized for a disease reduces the number of hospital days due to the disease 4-10 years later. The estimated elasticity when k=8 (when the Z value is largest) is -0.302: a 10% increase in the number of drugs for a disease reduces the number of hospital days due to the disease by 3.0% 8 years later.
In models 48-53, the regressor is ln(N_CHEM_SUBGROUPS i,t-k ) for k = 0, 1,…, 5, respectively. None of the coefficients are statistically significant. The number of hospital days is inversely related to the lagged number of drugs commercialized, but not the number of chemical subgroups.
Models 54-70 examine the effect of pharmaceutical innovation on the number of discharges. The coefficients in models 54-60 are insignificant, but the coefficients in models 61-63 are negative and significant. This indicates that an increase in the number of drugs commercialized for a disease reduces the number of hospital discharges due to the disease 7-9 years later. The magnitudes of the coefficients in models 61-63 are almost as large as the magnitudes of the coefficients in models 44-46, indicating that most (about 80%) of the reduction in hospital days attributable to pharmaceutical innovation is due to a reduction in the number of discharges, rather than a reduction in length of stay. Now we will estimate the magnitude of the reduction in hospital days that was attributable to growth in the number of substances commercialized. We do this by comparing the estimates of the year fixed effects ( t 's) in the following two versions of eq. (8):
Since eq. (10) We also know the active ingredient(s) ("molecules") contained in each product. The "molecules" identified in the IMS MIDAS database for Sweden do not coincide exactly with "chemical substances" identified in the Läkemedelsverket database. Table 6 example, for oral solid forms the standard unit factor is one tablet or capsule whereas for syrup forms the standard unit factor is one teaspoon (5 ml) and injectable forms it is one ampoule or vial. Standard units should be used when the packs or products being compared are different in form. Table 7 . The estimates of models [71] [72] [73] [74] [75] [76] indicate that the relationship between the growth in expenditure and the growth in the number of molecules 0-5 years earlier is statistically significant. Growth in the number of molecules 3 years earlier has the largest and most significant effect. A 10% increase in the number of molecules in a drug class is associated with an 8.9% increase in expenditure on that class 3 years later.
MANU_VALUE ct ). Estimates of eq. (12) are shown in
Earlier in this paper we estimated how much pharmaceutical innovation increased life expectancy and reduced hospital utilization during the period 2000-2009. We also wish to estimate how much pharmaceutical innovation increased pharmaceutical expenditure during the same period. The estimates in Table 7 Table 6 , during the period 1999-2010 the growth rate of the number of IMS molecules was 12% lower than the growth rate of Läkemedelsverket chemical substances.
The cost-effectiveness of pharmaceutical innovation in Sweden
We have presented estimates of the effect of pharmaceutical innovation on age at death (Table 3) , hospital utilization (Table 5) , and pharmaceutical expenditure (Table 7) . Now we will use these estimates to calculate the incremental cost-effectiveness of pharmaceutical innovation, Table 8 imply that the cost per life-year gained from the introduction of new drugs was $233 (= -$109/ -0.47 years), which is a very small fraction of leading economists' estimates of the value of (or consumers' willingness to pay for) a one-year increase in life expectancy.
Changes in any of the estimates or assumptions documented in Table 8 will, of course, change one's estimate of the ICER. A change that can substantially increase the ICER is reducing the estimate of the hospital cost reduction attributable to pharmaceutical innovation. If we assume that there is no hospital cost reduction, the ICER is $19,192. Even this figure is well below the consensus value of a statistical life-year.
Moreover, there are several good reasons to think that the calculations in Table 9 lead to an overestimate of the ICER. First, we may have underestimated the increase in life expectancy attributable to pharmaceutical innovation. Recall that pharmaceutical innovation accounted for a larger share (63%) of the increase in the fraction of deaths that occurred at an age greater than 75 than it did of the increase in mean age at death (31.6%). Also, life expectancy at birth (as conventionally defined) increased more than mean age at death between 2000 and 2009 (1.71 years vs. 1.40 years). Second, we may have overestimated the increase in pharmaceutical expenditure attributable to pharmaceutical innovation, because the growth rate of the number of IMS molecules was lower than the growth rate of Läkemedelsverket chemical substances. And third, in Table 8 we assumed that pharmaceutical innovation had no effect on other medical expenditure, but it may have reduced other medical expenditure-especially nursing home expenditure-as it appears to have reduced hospital expenditure. If we assume that the hospital cost reduction is half as large as that implied by model 45 in Table 5 -about 6% instead of 12%-and that pharmaceutical innovation also reduced other medical expenditure by 6%, pharmaceutical innovation would be cost-saving: the ICER is -$15,189.
Summary and conclusions
In this paper, we have used longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical expenditure in Sweden during the period 1997-2010. The measures of longevity we used were based on the age distribution of deaths caused by a disease in a given year. Our estimates do not capture between-disease spillover effects, but these effects appear to be quite modest in practice: almost all of the increase in mean age at death was due to within-disease increases, rather than a shift in the distribution of causes of death. The measure of pharmaceutical innovation we used was based on the number of drugs We then performed some sensitivity analysis, which indicated the effect of modifying the assumptions underlying the baseline ICER calculation. If we assume that there is no hospital cost reduction from pharmaceutical innovation, the ICER is $19,192. Even this figure is well below the consensus value of a statistical life-year. Moreover, there are several good reasons to think that our baseline calculation overestimates the ICER: we may have underestimated the effect of pharmaceutical innovation on life expectancy, and overestimated its effect on pharmaceutical expenditure. If we assume that the hospital cost reduction is half as large as our estimates indicate, and that pharmaceutical innovation also reduced other medical expenditure (e.g. nursing home expenditure) proportionally, pharmaceutical innovation would be cost-saving:
the ICER is -$15,189.
Pharmaceutical innovation is not the only type of medical innovation that is likely to contribute to longevity growth. Other medical innovation, such as innovation in diagnostic imaging, surgical procedures, and medical devices, is also likely to affect longevity growth.
Longitudinal disease-level measures of non-pharmaceutical medical innovation are not available for Sweden, but they are available for the U.S. during the period 1998-2007. But a previous analysis of the U.S. data suggests that failure to control for other medical innovation is very unlikely to result in overestimation of the effect of pharmaceutical innovation on longevity growth, and may even result in underestimation of this effect. 1990  191  399  673  1991  192  406  695  1992  194  416  723  1993  198  430  772  1994  200  438  804  1995  206  451  850  1996  209  465  902  1997  218  486  962  1998  227  504  1023  1999  231  518  1074  2000  232  530  1125  2001  234  540  1175  2002  238  550  1224  2003  241  556  1251  2004  242  560  1296  2005  246  568  1326  2006  248  577  1372  2007  250  585  1418  2008  250  588  1454  2009  253  600  1504  2010 253 607 1537 Table 7 Estimates of models of the effect of pharmaceutical innovation on pharmaceutical expenditure (eq. (12) 
